BMY - FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy
A novel approach to multiple myeloma treatment developed by Bristol-Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) took an important step toward commercialization on Tuesday when the Food and Drug Administration announced that it had accepted their application for approval of ide-cel, also known as bb2121.
A chimeric antigen receptor T-cell (CAR-T) therapy, ide-cel elicited a 73% overall response rate in multiple myeloma patients whose disease had returned following a median of three previous treatments.
IMAGE SOURCE: GETTY IMAGES.
For further details see:
FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy